Avalo Therapeutics’ (AVTX) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report released on Friday morning, Marketbeat.com reports.

Several other research firms have also commented on AVTX. Leerink Partners initiated coverage on shares of Avalo Therapeutics in a research report on Monday, July 6th. They issued an “outperform” rating and a $38.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Avalo Therapeutics in a research report on Wednesday, September 16th. Wall Street Zen downgraded Avalo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Weiss Ratings raised Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, Guggenheim set a $48.00 target price on Avalo Therapeutics and gave the company a “buy” rating in a research note on Friday, August 7th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $39.10.

Avalo Therapeutics Stock Performance

Shares of NASDAQ AVTX opened at $6.93 on Friday. The stock has a market cap of $371.66 million, a price-to-earnings ratio of -1.59 and a beta of 0.68. Avalo Therapeutics has a 52 week low of $6.53 and a 52 week high of $24.27. The company’s 50-day moving average price is $16.05 and its 200 day moving average price is $16.61.

Avalo Therapeutics (NASDAQ:AVTX) last posted its earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.25). As a group, research analysts expect that Avalo Therapeutics will post -2.95 earnings per share for the current year.

Insiders Place Their Bets

In other Avalo Therapeutics news, CFO Christopher Sullivan sold 12,394 shares of the company’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total value of $202,394.02. Following the transaction, the chief financial officer directly owned 39,900 shares in the company, valued at approximately $651,567. This represents a 23.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 23,258 shares of company stock valued at $395,434. Insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AVTX. Braidwell LP purchased a new position in shares of Avalo Therapeutics in the 2nd quarter worth about $30,107,000. Affinity Asset Advisors LLC grew its holdings in shares of Avalo Therapeutics by 27.6% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after purchasing an additional 289,786 shares during the period. Seven Fleet Capital Management LP grew its holdings in shares of Avalo Therapeutics by 34.3% during the 2nd quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company’s stock worth $14,244,000 after purchasing an additional 196,882 shares during the period. Squarepoint Ops LLC increased its position in Avalo Therapeutics by 624.9% during the 2nd quarter. Squarepoint Ops LLC now owns 589,245 shares of the company’s stock worth $10,889,000 after purchasing an additional 507,960 shares in the last quarter. Finally, Bank of America Corp DE increased its position in Avalo Therapeutics by 3.5% during the 1st quarter. Bank of America Corp DE now owns 643,000 shares of the company’s stock worth $9,600,000 after purchasing an additional 21,650 shares in the last quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Avalo Therapeutics

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Some analysts still see substantial upside. BTIG Research maintained a “buy” rating while setting a $10 price target, and Wedbush retained its “outperform” rating with a $22 target. Those targets imply meaningful potential appreciation from the recent trading level. BTIG Research recommendations Wedbush price target update
• Neutral Sentiment: Mixed analyst views remain. Guggenheim reaffirmed its “neutral” rating, while Wedbush’s decision to remain bullish provides some support despite its lower target. Guggenheim recommendations
• Neutral Sentiment: Trading was briefly halted under a limit-up/limit-down, or LULD, pause. The halt reflects heightened volatility but does not itself indicate a fundamental change in Avalo’s business.
• Negative Sentiment: AbbVie’s positive Phase 3 HS data appears to have weakened Avalo’s competitive position. Investors may view AbbVie’s results as increasing competition and reducing the perceived commercial opportunity for Avalo’s lead asset, resulting in selling pressure. AbbVie Phase 3 data article
• Negative Sentiment: Analyst sentiment has deteriorated. HC Wainwright downgraded Avalo from “buy” to “neutral,” while Wedbush reduced its price target from $34 to $22 despite keeping an “outperform” rating. The target reduction signals greater near-term uncertainty. HC Wainwright downgrade

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are intended to address conditions with significant unmet medical needs.

Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.